Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

The New York State Psychiatric Institute

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private

Established: 1895-01-01

Employees: 251

Market Cap: -

Website: http://www.nyspi.org

Clinical Trials

Pimavanserin for Rigid-compulsive Symptoms in Autism Spectrum Disorder

Phase 2

Recruiting

Conditions: Autism Spectrum Disorder

Interventions: Drug: Pimavanserin Tartrate 34 Mg ORAL CAPSULE [NUPLAZID]
Drug: Placebo

First Posted Date: 2023-08-21

Last Posted Date: 2025-05-13

Lead Sponsor: New York State Psychiatric Institute

Target Recruit Count: 30

Registration Number: NCT05999240

Locations: 🇺🇸
Wakarusa Research Facility, Lawrence, Kansas, United States
🇺🇸
Center for Autism and the Developing Brain, White Plains, New York, United States

Sleep Interventions and Neurocognitive Outcomes

Not Applicable

Not yet recruiting

Conditions: Amnestic Mild Cognitive Impairment
Sleep Disturbance

Interventions: Device: Acoustic slow-wave activity enhancement
Behavioral: Cognitive behavioral therapy for insomnia

First Posted Date: 2023-08-14

Last Posted Date: 2025-04-09

Lead Sponsor: New York State Psychiatric Institute

Target Recruit Count: 50

Registration Number: NCT05987007

Locations: 🇺🇸
New York State Psychiatric Institute, New York, New York, United States

rTMS and Cognitive-behavioral Therapy for Cocaine Use Disorder

Not Applicable

Not yet recruiting

Conditions: Cocaine Use
Cocaine Use Disorder
Cocaine Use Disorder, Moderate
Cocaine Dependence
Cocaine Use Disorder, Severe

Interventions: Device: Active H7-coil repetitive transcranial magnetic stimulation (rTMS)
Device: Sham H7-coil repetitive transcranial magnetic stimulation (rTMS)

First Posted Date: 2023-08-03

Last Posted Date: 2025-05-06

Lead Sponsor: New York State Psychiatric Institute

Target Recruit Count: 30

Registration Number: NCT05974202

Locations: 🇺🇸
New York State Psychiatric Institute (NYSPI) / Substance Treatment and Research Service (STARS), New York, New York, United States

Effects of rTMS on Food Choice in Anorexia Nervosa

Not Applicable

Suspended

Conditions: Anorexia Nervosa

Interventions: Device: High-frequency repetitive transcranial magnetic stimulation (active rTMS)
Device: Sham repetitive transcranial magnetic stimulation (sham rTMS)

First Posted Date: 2023-06-26

Last Posted Date: 2024-08-19

Lead Sponsor: New York State Psychiatric Institute

Target Recruit Count: 72

Registration Number: NCT05918835

Locations: 🇺🇸
New York State Psychiatric Institute, New York, New York, United States

Reducing Self-stigma Using Brief Video Intervention

Not Applicable

Completed

Conditions: Stigma, Social
Mental Health Disorder

Interventions: Behavioral: video

First Posted Date: 2023-05-26

Last Posted Date: 2023-05-26

Lead Sponsor: New York State Psychiatric Institute

Target Recruit Count: 1214

Registration Number: NCT05878470

Locations: 🇺🇸
New York State Psychiatric Institute, New York, New York, United States

A Pilot Study of SPG Block for PTSD

Early Phase 1

Completed

Conditions: Post Traumatic Stress Disorder

Interventions: Other: Sphenopalatine ganglion block

First Posted Date: 2023-02-24

Last Posted Date: 2024-02-16

Lead Sponsor: New York State Psychiatric Institute

Target Recruit Count: 6

Registration Number: NCT05743543

Locations: 🇺🇸
NYSPI, New York, New York, United States

Sublingual Dexmedetomidine for Treating Opioid Withdrawal

Phase 1

Recruiting

Conditions: Opioid Withdrawal
Opioid Use Disorder

Interventions: Drug: BXCL501 (240 micrograms)
Other: Placebo
Drug: BXCL501 (180 micrograms)
Other: Lofexidine (Positive Control)

First Posted Date: 2023-02-03

Last Posted Date: 2025-05-13

Lead Sponsor: New York State Psychiatric Institute

Target Recruit Count: 160

Registration Number: NCT05712707

Locations: 🇺🇸
Yale University, New Haven, Connecticut, United States
🇺🇸
Clinilabs, Eatontown, New Jersey, United States
🇺🇸
CenExel HRI, Marlton, New Jersey, United States

and more 1 locations

Glutamatergic Modulation as a Treatment for Depressive Symptoms Among Patients With Post-acute Sequelae of COVID (PASC): A Pilot Trial

Phase 2

Active, not recruiting

Conditions: Cognitive Dysfunction
Post-acute Sequelae of COVID-19
Depressive Symptoms

Interventions: Drug: CI-581a
Drug: CI-581b

First Posted Date: 2023-01-19

Last Posted Date: 2024-07-16

Lead Sponsor: New York State Psychiatric Institute

Target Recruit Count: 12

Registration Number: NCT05690503

Locations: 🇺🇸
New York State Psychiatric Institute, New York, New York, United States

Tailoring Overdose Education for Black Churches

Not Applicable

Suspended

Conditions: Opioid Overdose

Interventions: Behavioral: COEST

First Posted Date: 2022-12-09

Last Posted Date: 2024-08-22

Lead Sponsor: New York State Psychiatric Institute

Target Recruit Count: 96

Registration Number: NCT05645016

Locations: 🇺🇸
New York State Psychiatric Institute, New York, New York, United States

Repeated Administration of Cannabis Varying in THC and CBD

Phase 2

Suspended

Conditions: Cannabis

Interventions: Drug: Cannabis

First Posted Date: 2022-10-03

Last Posted Date: 2025-06-10

Lead Sponsor: New York State Psychiatric Institute

Target Recruit Count: 100

Registration Number: NCT05563948

Locations: 🇺🇸
New York State Psychiatric Institute, New York, New York, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy